RESUMEN
Objective To observe the clinical efficacy of Eureklin in the treatment of progressive cerebral infarction in young and middle-aged people outside the thrombolytic time window (the onset time was more than 6h).Methods From March 2016 to March 2019,120 young and middle-aged patients with progressive brain infarction who admitted to the neurology department of Chaonan Minsheng Hospital were selected and all patients were confirmed by cranial CT or MRI.They were divided into two groups by random drawing method.Clinical conventional therapy was applied in the control group (60 cases),and on the basis of conventional treatment,Eureklin intravenous drips was used in the treatment group (60 cases).Before and after treatment 14d,the national institutes of health stroke scale(NIHSS),daily living ability scale(ADL) were used to assessment of neurological impairment and Barthel index in patients.At the same time,the drug side effects and adverse reactions were observed.Results After treatment,the NIHSS score in the conventional treatment group[(3.4 ± 0.3)points] was lower than that in the Eureklin group[(4.1 ± 0.4) points],and the ADLscore in the conventional treatment group [(67.5 ± 24.8) points] was higher than that in the Eureklin group[(57.8± 26.7) points],the difference was statistically significant(t =0.014,0.003,all P ＜ 0.05).The total effective rate of the treatment group [83.33％ (50/60)] was higher than that of the control group [71.67％ (43/60)],the difference was statistically significant (x2 =3.596,P ＜ 0.05).At the same time,no serious adverse reactions were found in the Eureklin treatment group.Conclusion For young and middle-aged patients with progressive cerebral infarction outside the thrombolytic time window,the application of Eureklin can improve the patients' symptoms of neurological dysfunction,improve the ability of daily life,and without serious adverse events such as bleeding,which is worthy of clinical application.
RESUMEN
Objective To explore and compare the clinical efficacy of levetiracetam tablets and compound sodium valproate sustained release tablets in the treatment of children and adolescents with epilepsy.Methods From April 2017 to April 2018,80 children and adolescents with epilepsy treated in Chaonan Minsheng Hospital of Shantou were selected as study objects,and they were randomly divided into two groups by drawing lots,with 40 cases in each group.The observation group was given levetiracetam tablets,and the control group was treated with valproate.The improvement of EEG after therapy,the total effective rate,and the incidence of adverse reactions were observed and evaluated.Results The EEG improvement rates after treatment for 6 months in the observation group and control group were 41.17％,45.71％,respectively,the difference was not statistically significant(x2 =0.508,P ＞0.05).The EEG improvement rates after treatment for 9 months in the observation group and control group were 70.58％,74.28％,respectively,the difference was not statistically significant (x2 =0.225,P ＞ 0.05).The total effective rate in the observation group was 92.50％,which was 95.00％ in the control group,the difference was not statistically significant between the two groups (x2 =0.354,P ＞ 0.05).However,the incidence rate of adverse reactions of the observation group(22.50％) was significantly lower than that of the control group(45.00％)(x2 =6.864,P ＜ 0.05).Conclusion Both levetiracetam tablets and compound sodium valproate sustained release tablets have appreciable efficacy and safety in the treatment of epilepsy in children and adolescents,but levetiracetam therapy has less adverse reactions,which deserves further promotion in monotherapy of epilepsy in children and adolescents.
RESUMEN
ObjectiveTo explore the effects and significance of acetazolamide on the expression of aquaporin-4(AQP4) of gastric mucosal in rats with endotoxemia. Methods30 SD rats were randomly divided into 3 groups: Sham operated control group( Control group) ,endotoxemia group( EDT group) and acetazolamide group( ATL group).The immunohistochemistry was used to assess the expression of the AQP4 in the gastric mucosal tissues. The serum tumor necrosis factor-α(TNF-α) and interleukin-1 β(IL-1β) levels in each group were measured by radioimmunoassay. ResultsThe expression of AQP4 and the levels of serum TNF-αt and IL-1 ββ in EDT group were higher than those in control group( P ＜ 0.01 ). After the ALT treatment, the expression of AQP4 and the levels of serum TNF-α and IL1 β in ALT group were lower than those in EDT group( all P ＜0.01 ) and the expression of AQP4 in the gastric mucosal tissues in ALT group was also lower than those in EDT group( P ＜0.01 ). ConclusionThe raising of AQP4 expression and increasing of serum TNF-α, IL-1β take part in the progress of gastric mucosal injury in rats with endotoxemia. ALT could protect the gastric mucosal tissues by lowering the AQP4 expression and reducing the levels of serum TNF-α and IL-l β.